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Background With the aim of populating the Lives Saved Tool (LiST) with
parameters of effectiveness of existing interventions, we conducted
a systematic review of the literature assessing the effect of
Haemophilus influenzae type b (Hib) and pneumococcal (PC) conju-
gate vaccines on incidence, severe morbidity and mortality from
childhood pneumonia.
Methods We summarized cluster randomized controlled trials (cRCTs) and
case–control studies of Hib conjugate vaccines and RCTs of 9- and
11-valent PC conjugate vaccines conducted in developing countries
across outcome measures using standard meta-analysis methods.
We used a set of standardized rules developed for the purpose of
populating the LiST tool with required parameters to promote com-
parability across reviews of interventions against the major causes
of childhood mortality. The estimates could be adjusted further to
account for factors such as PC vaccine serotype content, PC serotype
distribution and human immunodeficiency virus prevalence but this
was not included as part of the LiST model approach.
Results The available evidence from published data points to a summary
effect of the Hib conjugate vaccine on clinical pneumonia of 4%, on
clinical severe pneumonia of 6% and on radiologically confirmed
pneumonia of 18%. Respective effectiveness estimates for PC vac-
cines (all valent) on clinical pneumonia is 7%, clinical severe pneu-
monia is 7% and radiologically confirmed pneumonia is 26%.
Conclusions The findings indicated that radiologically confirmed pneumonia, as
a severe morbidity proxy for mortality, provided better estimates for
the LiST model of effect of interventions on mortality reduction
than did other outcomes evaluated. The LiST model will use this
to estimate the pneumonia mortality reduction which might be
observed when scaling up Hib and PC conjugate vaccination in
the context of an overall package of child health interventions.
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Background
According to a UNICEF-WHO report from 2006, over
two million children die from pneumonia each year,
accounting for almost one in five under-5 deaths
worldwide.1 The estimated incidence of clinical pneu-
monia in children aged <5 years in developing coun-
tries is 0.28 episodes per child-year, whereas in
developed countries is 0.05 episodes per child-
year.2,3 WHO recommends routine immunization pro-
grammes including measles, pertussis, Haemophilus
influenzae type b (Hib) conjugate and pneumococcal
(PC) conjugate vaccines, in order to prevent
pneumonia.
Hib conjugate vaccines were developed during the
late 1980s and involved conjugation of polyribistol-
phoshate (PRP) to carrier proteins such as diphtheria
toxoid conjugate (PRP-D). Other HibCV formulations
include PRP covalently conjugated to other proteins
carriers. These included mutant diphtheria toxin con-
jugate (PRP-CRM197), meningococcal outer mem-
brane protein conjugate (PRP-OMP) and tetanus-
toxoid protein (PRP-T).4 The seven-valent PC conju-
gate vaccine (PCV7), which includes the seven most
common pneumococcal serotypes found in industria-
lized countries and uses CRM197 as a protein carrier,
was first licensed in the USA (2000) and today is
licensed in 90 countries and adopted in immuniza-
tion programmes in 26 countries.5
Thanks to the efforts of Global Alliance for Vaccines
and Immunization (GAVI Alliance), The Hib Initiative
and The Pneumococcal vaccines Accelerated
Development and Introduction Plan (PneumoADIP),
the majority of GAVI Alliance eligible countries have
now introduced Hib vaccine (http://www.hibaction
.org). The coverage of the PC vaccine is still very lim-
ited in the areas where it is needed most6; however,
efforts to improve its coverage are underway (http://
www.preventpneumo.org). As of early 2009, GAVI
Alliance has officially approved support for PC vaccine
introduction in 11 developing countries, most of them
in Africa, but 72 countries are eligible for GAVI Alliance
funding and additional approvals are expected.
This report reviews data from several studies and
presents evidence of the effectiveness of the Hib and
PC conjugate vaccines in order to provide parameters
needed for the Lives Saved Tool (LiST) software to
model the preventable deaths of childhood pneumo-
nia and to transparently document all steps of this
process, thus assisting to the transparency and
wider acceptance of LiST tool. The reviews of effec-
tives of the interventions are shaped in large part by
the needs of the LiST model. In that model, increases
in coverage of an intervention results in a reduction of
one or more cause-specific deaths or in reduction of a
risk factor. Therefore, the reviews and the grade pro-
cess used were designed to develop estimates of the
effect of an intervention in reducing either a risk factor
or a death due to specific cause. For more details of
the review methods, the adapted grade approach or the
LiST model see other articles in this supplement.
In addition, we used an approach that was carefully
standardized across all the groups of investigators,
who addressed the main causes of childhood deaths.
The approach focuses on published results which were
not then subject to any subsequent detailed modelling
(i.e. there was no attempt to account for population
differences such as differing national or regional ser-
otype distributions or varying zinc deficiency preva-
lence; or for differences in interventions such as
vaccine valency or zinc dose). This systematically
applied and objective approach facilitates the standard
presentation across all child health interventions of
tables giving key details of the studies reviewed and
of the outcome data reported.
Methods
Identification and selection of studies
We attempted to identify all randomized controlled
trials (RCTs), quasi-RCTs or observational studies
investigating the effect of PC or Hib conjugate vac-
cines on pneumonia related outcomes in children less
than 5 years old. Trials were identified from the
following databases: Medline (1970 to August 2008);
EMBASE (1970 to August 2008) and the Cochrane
Central Register of Controlled Trials (CENTRAL)
(The Cochrane Library, Issue 3, 2008). Search terms
included various combinations of: Pneumococcal vac-
cines, Haemophilus vaccines, and pneumonia. In addition,
relevant studies were identified by searching the ref-
erences of the selected studies and the PneumoADIP
(http://www.preventpneumo.org/index.cfm) and Hib
initiative (http://www.hibaction.org/) websites.
Eligible studies were selected according to the
pre-determined inclusion criteria (7). In particular:
(i) included studies: (a) were RCTs, quasi-RCTs or
observational studies, (b) had a control arm of pla-
cebo or no treatment and (c) were conducted in a
developing country; (ii) children of included studies
were (a) <5 years old and (b) were followed up until
52 years of age (not applicable for the case–control
studies); (iii) the main types of outcome measures
were: (a) pneumonia-specific mortality, (b) all-cause
mortality, (c) WHO-defined or predefined radiologi-
cally confirmed pneumonia, (d) clinical severe pneu-
monia and (e) clinical pneumonia. There were no
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language or publication restrictions. In addition, a
parallel review was conducted by two independent
investigators (SJ and AJ) and results from the two
searches and study selections were compared and
merged.
Abstraction, quality assessment and
meta-analyses
Data from all studies that met final inclusion and
exclusion criteria were abstracted into a standardized
form for each outcome of interest. We abstracted key
variables with regard to the study identifiers and con-
text, study design and limitations, intervention spe-
cifics, and outcome effects. The quality of each study
was assessed and graded according to the Child Health
Epidemiology Reference Group (CHERG) adaptation
of the GRADE technique (‘GRADE Profiler version
3.2’ scoring system) (Supplementary Table a).
We summarized the evidence by outcome including
qualitative assessment of the quality of each specific
outcome (Supplementary Table b). In addition, for
any outcome with more than one study a meta-
analysis was conducted and reported pooled relative
risk (RR) and corresponding 95% confidence interval
(CI) using the fixed effect model (Mantel-Haenszel
method).8 In case of heterogeneity (P< 0.1) the
random effect model (DerSimonian-Laird method)
was applied (although it is recognized that due to
the variation in precise interventions, study methods
and outcome definitions the meta-estimates should be
interpreted cautiously). All analyses were conducted
using STATA 10.0 statistical software.
For the outcome of interest, namely the effect of PC
or Hib on pneumonia mortality, we applied the
CHERG Rules for Evidence Review to the collective
pneumonia morbidity and mortality outcomes, to gen-
erate a final estimate for reduction in pneumonia
mortality (Supplementary Table c). The final version
of the paper was presented and peer-reviewed by the
CHERG committee.
Results
We identified 323 titles from the search conducted in
Medline, 333 from Embase and 98 from CENTRAL.
After elimination of duplicates, studies dealing only
with safety and/or immunogenicity, studies with
alternative outcome parameters (e.g. otitis media,
meningitis), studies conducted in industrialized coun-
tries, review articles and studies which did not fit the
inclusion criteria, a total of 13 studies were extracted
from the bibliographic databases (Figure 1). One RCT
on the effect of seven-valent PC vaccines was
excluded from the analysis, because it was not con-
ducted in a developing country.9
The characteristics of the studies that were identi-
fied to estimate the effect of Hib vaccines on pneu-
monia mortality are presented in Supplementary
Table 1. A summary of the identified outcomes as
well as their exact definitions are presented in
Supplementary Table 2a. In particular for Hib conju-
gate vaccines, the following outcomes were identified:
(i) one cluster randomized controlled trials
(cRCT)10 reporting pneumonia mortality
outcomes;
(ii) one cRCT10 and one RCT11 reporting all-cause
mortality outcome;
(iii) two cRCTs10,12 one RCT11 and three case–con-
trol studies13–15 reporting radiologically con-
firmed pneumonia,
(iv) two cRCTs10,12 and one RCT11 reporting clinical
severe pneumonia and
(v) one cRCT10 and one RCT11 reporting clinical
pneumonia.
The characteristics of the studies that were identi-
fied to estimate the effect of PC vaccines on pneumo-
nia mortality are presented in Supplementary Table 1.
A summary of the identified outcomes as well as their
exact definitions are presented in Supplementary
Table 2b. In particular for PC conjugate vaccines,
the following outcomes were identified:
(i) one 9-valent RCT reporting lower respiratory
tract infection (LRTI) specific mortality,16
(ii) two 9-valent RCTs reporting all-cause
mortality,16,17
(iii) two 9-valent17,18 and one 11-valent RCT19
reporting radiologically confirmed pneumonia,
(iv) two 9-valent RCTs16,17 and one 11-valent
RCT19reporting clinical severe pneumonia and
(v) two 9-valent17,18 and one 11-valent RCT19 on
clinical pneumonia.
In Tables 1 and 2 we report the quality assessment
of studies by outcome and results from corresponding
meta-analyses for the Hib and PC vaccines, respec-
tively. With respect to the Hib vaccines, although
there was an estimate of pneumonia mortality [clin-
ical or verbal autopsy defined; 7% (95% CI –7, 19%)],
the specific outcome quality of evidence was very low
(since the estimate was based on one study which
was not adequately powered to address this outcome)
(Table 1). Therefore, the effect of Hib vaccines on
pneumonia mortality was estimated by using the radi-
ologically confirmed pneumonia summary effect
(according to the CHERG Rules 1 and 5 for
Evidence Review) (Table 1, Figures 2 and 3) based
on the rationale that effect on a relatively severe
pneumonia outcome might serve as a proxy for an
effect on pneumonia mortality in the absence of
high quality evidence on the latter. The summary
effect of the Hib conjugate vaccine on radiologically
confirmed pneumonia was 18% (95% CI –2, 33%)
estimated by combining one RCT, two cRCTs and
one case–control study that used systematic vaccine
allocation and therefore included in the analysis.
Regarding the other pneumonia related outcomes, the
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effect of Hib conjugate vaccines on all cause-mortality
was 5% (95% CI –4, 14%), on clinical severe pneumonia
was 6% (95% CI 1, 11%) and on clinical pneumonia
was 4% (95% CI 3, 6%) (Table 1, Figure 3).
For the PC conjugate vaccines, although there was
an estimate of LRTI specific mortality [18% (95%
CI 52, 56%)], the specific outcome quality was
very low (since the estimate was based on one
study with less than 50 events) (Table 2). Therefore
according to the CHERG Rules 0, 1 and 5 for Evidence
Review in order to estimate the effect on pneumonia
mortality, we used the effect of PC vaccines on radi-
ologically confirmed pneumonia, which was 26%
(95% CI 12, 37%) (Tables 1 and 2, Figure 4).
Regarding the other pneumonia related outcomes,
the effect of PC vaccines [all valent) on all-cause mor-
tality was 15% (95% CI 2, 26%)], on clinical severe
pneumonia was 7% (95% CI –1, 14%) and on clinical
pneumonia was 7% (95% CI –2, 15%). One study (ref.
for Klugman) reported outcomes separately for
human immunodeficiency virus (HIV) positive and
HIV negative children. Outcomes for HIV positive chil-
dren were examined separately and are summarized
here: LRTI specific mortality: –3% (95% CI –23, 20%);
all cause mortality: 6% (95% CI –16, 24%); radiologi-
cally confirmed pneumonia: 13% (95% CI –7, 29%);
clinical severe pneumonia: 17% (95% CI 5, 27%); clin-
ical pneumonia: 15% (95% CI 5, 24%).
Finally, we undertook the jacknife approach, where
we serially removed one study and then re-run the
meta-analysis for the effect of the Hib or PC vaccines
on radiologically confirmed pneumonia to indicate
whether the meta-analysis results are influenced by
the findings of one study. The results of this approach
are presented in Supplementary Table 3.
Discussion
Estimation of direct vaccine effect on
pneumonia mortality
The identified studies were grouped according to the
specific outcomes and were given an overall quality
judgment assessed by applying the GRADE approach
(Supplementary Table b). To translate the evidence of
the collective pneumonia morbidity and mortality out-
comes into a final estimate of effectiveness of redu-
cing cause-specific mortality, we applied the CHERG
Rules for Evidence Review (Supplementary Table c).
In particular for Hib vaccines, the pneumonia mortal-
ity and all cause mortality outcome were dropped out,
since the initial quality of evidence of these outcomes
was very low since these trials were not designed to
measure mortality (Rule 1). Therefore, to estimate the
effect of Hib vaccines on pneumonia mortality we
used the estimate of the effect on radiologically
656 papers identified (Medline)
38 papers reviewed for eligibility
Titles and abstracts screened
Papers screened for relevant outcome measures
6 papers identified for abstraction
(Hib Vaccines)
Pneumonia mortality (n=1)
Radiologically confirmed
pneumonia (n=6)
Severe pneumonia (n=3)
Clinical pneumonia (n=2)
6 papers identified for abstraction
(PC Vaccines)
LRTI mortality (n=1)
All cause mortality (n=2)
Radiologically confirmed
pneumonia (n=3)
Severe pneumonia (n=3)
Clinical pneumonia (n=3)
All-cause mortality (n=2)
Figure 1 Synthesis of study identification in review of the effects of Hib or PC vaccines on pneumonia mortality, all-cause
mortality, radiologically confirmed pneumonia, clinical pneumonia, invasive Hib disease and invasive pneumococcal disease
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confirmed pneumonia (Rule 5; combined RR 0.82,
95% CI 0.67, 1.02). To estimate the effect of PC vac-
cines on pneumonia mortality we used the estimate
on radiologically confirmed pneumonia (Rule 5; com-
bined RR 0.74, 95% CI 0.63, 0.88) since the estimate of
the effect on pneumonia mortality (for HIV– children)
was based on less than 50 events (Rule 0), the quality of
the estimate on pneumonia mortality (for HIVþ
children) was very low (Rule 1) and the outcome
all-cause mortality was initially very low and there-
fore had to dropped out after the quality adjustment
(Rule 1).
The question of how to estimate best the pneumonia
mortality effects of Hib and PC vaccines from out-
comes observed and reported in the published rando-
mized controlled trials (e.g. morbidity, radiological
Outcome Measures Application of Standard Rules
Radiological pneumonia (cRCTs/ RCT/ 
case-control, n=4; 1302 events) Hib vaccine 
reduces radiologically confirmed pneumonia by 
18% (-2, 33%) Rule 5: APPLY
Radiological pneumonia (case-control, n=2; 
656 events) Hib vaccine reduces radiologically 
confirmed pneumonia by 45% (15, 68%)
Clinical severe pneumonia (cRCT/ RCT, 
n=3; 5304 events) Hib vaccine reduces severe 
pneumonia by 6% (1, 11%)
Clinical pneumonia (cRCT/ RCT, n=2; 31227 
events) Hib vaccine reduces clinical 
pneumonia by 4% (3, 6%)
All cause mortality (cRCT/ RCT, n=2, 1703
events) Hib vaccine reduces all cause mortality 
by 5% (-4, 14%)
Rule 1: Do not apply
>50 events but very 
low quality of evidence
Pneumonia mortality (cRCT, n=1, 750
events) Hib vaccine reduces pneumonia 
mortality by 7% (-7, 19%)
Rule 1: Do not apply
>50 events but very 
low quality of evidence
Figure 3 Application of standardized rules for choice of final outcome to estimate effect of Hib conjugate vaccines on the
reduction of pneumonia mortality
Figure 2 Forest plot for the effect of Hib conjugate vaccines on radiologically confirmed pneumonia; RCTs (light grey),
cRCT (dark grey), c/c (black)
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confirmed pneumonia, severe morbidity) is unre-
solved. We have elected to base this on effects on
radiological confirmed pneumonia but the degree to
which this decision is valid is uncertain. The Gambian
study showed that even though the case fatality ratio
was greater for radiological confirmed pneumonia, the
number of pneumonia deaths for non-radiologically
confirmed pneumonia was the same for that of radi-
ologically confirmed pneumonia, dispelling the idea
that all severe pneumonia would fulfil the criteria of
‘radiologically-confirmed’20 There is also evidence to
show that not all bacterial pneumonia presents as
radiological pneumonia. In the South Africa study,
only 36% of the prevented PC pneumonia cases
were radiologically confirmed. In The Gambia, this
percentage was closer to 85%.
Outcome definitions
The definitions of radiologically confirmed pneumo-
nia, clinical severe pneumonia and clinical pneumonia
are not always clear or defined in the same way
across the publications we included in the
meta-analysis. In particular, definitions of pneumonia
morbidity outcomes were not standardized between
the Hib vaccine clinical trials, whereas they were
Figure 4 Forest plot for the effect of PC conjugate vaccines on radiologically confirmed pneumonia; 9-valent (dark grey)
and 11-valent (black) RCTs
Outcome Measures Application of Standard Rules
Clinical pneumonia (RCT, n=3; 7876 events)
PC vaccine reduces clinical pneumonia by 7% (-
2, 15%)
Radiological pneumonia (RCTs, n=3; 1619 
events) PC vaccine reduces radiologically 
confirmed pneumonia by 26% (12, 37%)
LRTI mortality (RCT, n=1; 40 events)
PC vaccine reduces LRTI mortality in HIV-
children by 18% (-52, 56%)
Rule 0: Do not apply
<50 events
All cause mortality (RCT, n=2; 791 events)
PC vaccine reduces all cause mortality by 
15% (2, 26%)
Clinical severe pneumonia (RCT, n=3; 2397 
events) PC vaccine reduces severe pneumonia 
by 7% (-1, 14%)
Rule 5: APPLY
Rule 1: Do not apply
>50 events but very 
low quality of evidence
Figure 5 Application of standardized rules for choice of final outcome to estimate effect of PC conjugate vaccines on the
reduction of pneumonia mortality
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standardized between the PC vaccine trials. In addi-
tion, radiologically positive cases detected when
admitted to hospital rather than in the community
may be biased to ward including children who may
have failed first line therapy targeting pneumococcus
and Hib and therefore in whom the aetiology of pneu-
monia is less likely to be pneumococcus or Hib.
Standardization in definitions of radiological pneumo-
nia between studies was carried out but not all factors
which influence radiographic were standardized. For
example, more intense community surveillance (and
related treatment) may paradoxically reduce the like-
lihood of pneumococcus (or Hib) presenting as radi-
ological pneumonia. Also, issues such as access to
antibiotic treatment and access to health care may
all impact on the radiographic presentation of PC
and Hib pneumonia. These issues may explain some
of the differences for Hib effectiveness estimates for
radiologically confirmed pneumonia between
Indonesia and The Gambia, as well as for PC effec-
tiveness estimates between The Gambia setting and
the settings in South Africa and Philippines.20 The
latter differences in the PCV trials might also be
explained by the different background epidemiology
of these settings (high child mortality—low income
in The Gambia setting and lower child mortality—
middle income in the South Africa and Philippines
settings). However, we would not consider segment-
ing the effectiveness estimate and apply different esti-
mates in different sets of countries, mainly because
there are only few data-points.
Regarding the severe clinical pneumonia outcome, if
severe pneumonia were identified when admitted to
the hospital, then these cases would be consistent
with the current CHERG published estimates of
severe childhood pneumonia episodes (incidence rate
of severe clinical pneumonia: 0.02–0.04 episodes/
child-years).2,3 However, if these cases are defined
on signs such as indrawing only at the community
level this would likely represent a more diverse
group of pneumonia cases. The definition of ‘clinical
pneumonia’ in these studies was consistent with the
definition which was most frequently used in epide-
miological studies estimating pneumonia incidence
and also with and the current estimate of the
number of pneumonia cases globally (incidence rate
of clinical pneumonia: 0.29 episodes/child-years).2,3
Parameters influencing estimates of direct
vaccine effect on pneumonia mortality
Although it is not included in the standardized review
process for the LiST model, it is be possible to adjust
the vaccine effectiveness summary estimate for the
valency of the PC vaccine studied, for the age specific
serotype distribution of the study population and for
the HIV prevalence in the study population. This has
been attempted and reported by other groups.22
For pneumococcal vaccine, effectiveness depends on
serotype distributions across the world and is likely to
provide different levels of effectiveness for different
regions. The distribution of serotypes in the local pop-
ulation is important, and estimates of the direct effect
of the vaccine should ideally be adjusted to account
for the proportion of circulating pneumococci that are
vaccine type. However, data on serotype distribution
are currently incomplete and estimates of the propor-
tion of vaccine serotypes among circulating PC by
region of the world vary.23,24 Increased availability
of data on aetiological spectrum of childhood pneu-
monia at the community level and on serotype distri-
butions in particular will provide much needed
evidence base for modelling the effect of the vaccines
(http://www.preventpneumo.org). As new vaccines
become available, the coverage of serotypes will
need to be adjusted accordingly to cover the wider
range of serotypes included in these vaccines. For
Hib conjugate vaccine regional differences may also
exist if Hib is a less important problem in Asia than
in Africa.
Vaccine effectiveness in areas where HIV is a major
problem may substantially differ from the estimates
in regions where HIV is not such a problem. More
published data on this issue is required to be able
to address this properly, because good quality data
is currently restricted to one source—a study in
Soweto in South Africa18 Thus, more evidence is
required to model the differential impact in
HIV-affected regions.
As noted above, the LiST approach has decided not
to employ such adjustments of published trial data for
any of the child health interventions reviewed and, in
any case, any modelling process would be challenging
due to the sparse evidence base.
Other vaccine effects (not included in the
current review)
Positive indirect effects
The Hib and PC vaccines have an important impact on
reducing carriage of the pathogenic organisms in vac-
cinated children and by reducing the pool of infec-
tious children in the community, and are thus
expected to confer a significant degree of indirect pro-
tection by protecting unvaccinated children, including
young infants. This has been indirectly shown by the
reduction in invasive pneumococcal disease in chil-
dren less than 2 months of age in the USA as well
as among only partially vaccinated infants.25
To measure the positive indirect effect for conjugate
Hib vaccination, one approach has been to compare
the reduction in invasive Hib disease observed several
years after vaccine introduction, with the reported
coverage of the third dose. Using this approach, the
overall effect on invasive Hib disease was estimated to
be 15–30% points higher than the reported coverage
of three doses, with a herd immunity threshold (i.e.
elimination) at around 85% coverage of the third
dose.26 However, a case control study conducted
5 years after vaccine introduction in the Gambia has
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demonstrated a similar effect for Hib pneumonia,
with short-term elimination of all invasive Hib disease
following 68% coverage of three doses. This was
achieved despite a significant number of the doses
being administered later than the peak age of invasive
Hib disease,27 although cases of both Hib pneumonia
and Hib meningitis had started to re-emerge a few
years later,28
For pneumococcal conjugate vaccine, the most
robust information on positive indirect effects is
based on a comparison of pneumonia hospital admis-
sions in the pre-vaccine era (1997–1999) and
post-vaccine era (2001–2004) in the USA.29 In this
study, clear herd immunity benefits were observed
in older unvaccinated children and adults with the
following reductions estimated for ‘all-cause’ pneu-
monia admissions: 18% (5–17 years), 26% (18–
39 years), 19% (40–64 years) and 15% (65þ years).
In the age group targeted by the vaccination pro-
gramme (<2 years), the reduction in ‘all-cause’ pneu-
monia was 39% but it is not clear how much of this
benefit can be attributed to the herd effect. One
approach is to use the reported 65% reduction in
pneumonia admissions caused by pneumococcal, and
to derive the direct effect by assuming: (i) reported
vaccination coverage of 73% (68–83%); (ii) 80% prev-
alence of pneumcoocci that are vaccine type30; and
(iii) 94% vaccine efficacy (9). This rather crude
back-calculation gives a direct effect in the region
of 55% (51–62%) and suggests that indirect effects
may have contributed 15% (5–22%) of the total
benefit in children aged <2 years. A separate analysis
of all invasive pneumococcal disease from eight
states in the USA 5 years after PCV7 introduction esti-
mated the contribution of indirect effects to be
around 20% of the total benefit in children aged
<5 years.31
For both Hib and SP vaccines, the size of the herd
effect will be influenced by the number of doses and
intervals between them32 the coverage and timeliness
of vaccination programmes33,34 and the underlying
patterns of close contact within the local population.35
Positive indirect vaccine effects are important and
have to be addressed in some way in any models
that estimate their potential impact, however, the
dynamics of S. pneumonia in developing countries
needs further study to delineate whether it is the
same as in industrialized countries. The LiST model
will reflect this in an ‘effective vaccine coverage’ esti-
mate which will be based on empiric data on the
indirect effect from published sources.
Negative indirect effects
Pneumococcal conjugate vaccines may also be asso-
ciated with a negative indirect effect of serotype
replacement. This has been seen most notably
among Alaskan native and aboriginal populations36,37
where a negligible long-term effect on ‘all-cause’
pneumonia has been observed. Some increases in
invasive pneumococcal disease attributed to
non-vaccine types (19 A) have also been observed
coincided with the routine immunization programme
in the USA. This replacement was significantly out-
weighed by reductions in other serotypes,38 but the
long-term impact of serotype replacement remains
uncertain, and the impressive results of PCV7 in the
USA should be transferred to other settings with
some caution. Indeed, the size of these indirect vac-
cine effects (both positive and negative) is likely to be
specific to the local epidemiological and geographical
circumstances.
Antibiotic resistance
An additional long term benefit of the implementa-
tion of Hib and PC vaccination programmes is their
expected contribution to the reduction of antibiotic
resistance by reducing both the number of respiratory
illnesses and therefore the number of antibiotic pre-
scriptions.39 Results from two studies conducted in
California (1995–1998) and the USA (1997–2004)
have demonstrated that administration of 7 valent
PC vaccines reduced the number of antibiotic pre-
scriptions by 35 and 42% respectively,40,41 which is
potentially helpful to contain drug-resistant
Streptococcus pneumoniae since the level of antibiotic
use drives the rise in antibiotic resistance.42
More directly and immediately, five of seven sero-
types in the seven valent PC vaccines, introduced for
infants in the USA in 2000, are responsible for most
penicillin-resistant infections43 and the rate of
antibiotic-resistant invasive pneumococcal infections
decreased in young children (and older persons)
after the introduction of PC vaccines.43 However, con-
tinued exposure of non-PCV7 serotypes to antibiotic
pressure may reduce the overall impact of PCVs on
drug resistance.42 In addition, the gain from this vac-
cine effect will be partially eroded over time as
vaccine-included serotypes are replaced by resistant
clones of non vaccine types.44
Future vaccine developments
GlaxoSmithKline’s 10-valent pneumococcal conjugate
vaccine has just received license in the European
Union. In addition, newer vaccine formulations
currently being evaluated and licensed include formu-
lations consisting of 10 or 13 PC serotypes, which
will broaden coverage of the selected pneumococcal
serotypes commonly identified in developing coun-
tries. (http://www.preventpneumo.org). It is probable
that the 13-valent 2010 will have a larger effect
than that of the 9- and 11-valent vaccines. Thus,
this review may under-estimate the impact of
any future conjugate vaccines, which have a better
coverage of the main serotypes that account for
mortality.
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Conclusion
The estimates presented in this paper represent only
the first step in thinking about vaccine effectiveness
against childhood pneumonia and they should be
looked in parallel with estimates published from
other groups. As noted above the LiST approach for
review of effect of interventions on childhood mortal-
ity has not introduced scaling of estimates to take
account of varying populations or interventions—in
this case varying vaccine serotype distributions, vary-
ing prevalence of HIV, varying vaccine serotype com-
positions, and due to the effect of concurrent Hib
immunisation in PCV trials. In addition, it could be
argued that any pneumonia mortality reduction esti-
mates should ideally be considered along with infor-
mation on overall child mortality rates in the setting
in which the study was undertaken. For example, the
vaccine may have less impact on mortality where
access to care is high and overall child mortality
rates are low, but it may still substantially reduce
the incidence of chest X-ray positive pneumonia.
Bearing these points in mind, we can conclude at
this stage that the available evidence points to the
summary effect of the Hib conjugate vaccine on clin-
ical pneumonia of 4%, on clinical severe pneumonia
of 6% and on radiologically confirmed pneumonia of
18%. Respective effectiveness estimates for PC vac-
cines (all valent) on clinical pneumonia is 7%, on
clinical severe pneumonia is 7% and on radiologically
confirmed pneumonia is 26%. Therefore, the inferred
effectiveness of Hib and PC vaccines against pneumo-
nia mortality (based on the effectiveness against radi-
ologically confirmed pneumonia) is estimated to be 18
and 26%, respectively. These estimates will be
adjusted further in List to account for the indirect
positive effects due to herd immunity.
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KEY MESSAGES
 Findings of this review indicated that the summary effect of Hib and PC conjugate vaccines on
radiologically confirmed pneumonia was 18% and 26% respectively.
 Radiologically confirmed pneumonia will be used as a severe morbidity proxy for pneumonia mor-
tality in the LiST model.
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